This content was created in 2020, but has been reviewed and approved by the Training & Education Committee as useful, accurate, and relevant. Please note that in the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.
AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.
This webinar does not contain continuing education credit (CME and CMLE)
 |
 |
|
Speaker: Nikoletta Sidiropoulos, MD |
Moderator: Anthony Snow, MD |
This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.
Description:
The mesenchymal epithelial transition factor (MET) gene encodes a receptor tyrosine kinase. MET juxtamembrane (JM) splicing variants or exon 14 skipping variants result in loss of exon 14 containing the JM domain of MET. As this domain is a negative regulator of MET the net result is oncogenic. Targeted therapies have been shown to be effective therapeutic options in some clinical settings when this variant type is present. Data is well developed in non-small cell carcinomas of the lung and ongoing trials in other solid tumors are underway as these variants are variably present in multiple tumor types at frequencies of approximately 1-4%. The scientific background information, testing techniques, and clinical applications of this biomarker will be discussed.
Learning Objectives:
- Describe the underlying molecular biology of METex14 mutations.
- Review technical approaches for the detection of METex14 mutations.
- Discuss the clinical relevance of METex14 mutations.
Recording Date: September 29, 2020
Duration: 1 hr
Level of Instruction: Basic
This webinar does not contain continuing education credit (CME and CMLE)
This webinar is part 3 of the Emerging and Evolving Biomarkers Series.
This program has been supported through an educational grant from Bristol-Myers Squibb.
.jpg){kind=small}
AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC. IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.
Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.
Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
